Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ciclesonide (Alvesco)
ciclesonide · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | ciclesonide 50 and 200ug |
| 2 | ACTIVE_COMPARATOR | ciclesonide 100ug and 400ug |
| Name | Type | Description |
|---|---|---|
| ciclesonide | DRUG | low dose- 50ug and 200ug |
Inclusion Criteria: * stable asthma not on maintenance asthma medications * exercise induced bronchoconstriction on dry air exercise challenge. Exclusion Criteria: * other significant co-morbidity or treatments that might interfere with the conduct or results of the study * fail to return to base...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Ciclesonide is an inhaled small molecule developed for the treatment of asthma. It is being studied in a Phase 3 clinical program in respiratory medicine, with a completed trial evaluating its effect on exercise induced bronchoconstriction in patients with asthma.
Ciclesonide targets NR3C1, the glucocorticoid receptor, and acts as an agonist at this receptor. This target class places ciclesonide among the corticosteroid class of respiratory therapies used to manage airway inflammation in asthma.
Ciclesonide is developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company is responsible for the clinical development program for the drug in asthma.
Ciclesonide is in Phase 3 clinical development for asthma. It is an investigational small molecule and is not described as approved; the development program includes one completed Phase 3 trial, with no active trials currently listed.
Ciclesonide has been studied in the completed Phase 3 trial NCT00525772, titled Effect of Ciclesonide on Exercise Induced Bronchoconstriction. The trial enrolled 26 participants with asthma in Canada, was randomized, double blind, and active controlled, and included participants aged 12 years and older.